Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Center for International Blood and Marrow Transplant Research
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06859424CT.gov A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation | — | Recruiting | — | — | — |
NCT02356159CT.gov Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | — | Completed | — | — | — |
NCT00570999CT.gov Palifermin After Haploidentical PBSCT | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Palifermin (this asset) | Center for International Blood and Marrow Transplant Research | P2 | B · 60 |
| Fludarabine | Sawa Ito, MD | P2/3 | BB |
| Cyclophosphamide | Sawa Ito, MD | P4 | BB |
| Cytarabine | Janssen Research & Development, LLC | P2/3 | BB |
| Busulfanum | Sawa Ito, MD | P4 | BB |
| Etoposide | SWOG Cancer Research Network | P2/3 | BB |
| Methotrexate | SWOG Cancer Research Network | P3 | BB |
| Tacrolimus | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Nivestim | Kura Oncology, Inc. | P2 | BB |
+42 more in the Acute Leukemia cohort
Other indications for Palifermin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mucositis | — | P3 | BB · 64 |
| Non-Hodgkin Lymphoma | — | P4 | B · 63 |
| Plasma Cell Myeloma | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Palifermin in Acute Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/palifermin-acute-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →